Recommendation of the President – Revestive (teduglutide)
On 10 January 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 165/2024 on the appropriateness of granting reimbursement approval for Revestive (teduglutide) for the indication: short bowel syndrome